Vestcor Inc Buys 3,300 Shares of BioNTech SE (NASDAQ:BNTX)

Vestcor Inc increased its stake in BioNTech SE (NASDAQ:BNTX) by 50.0% in the 4th quarter, HoldingsChannel.com reports. The firm owned 9,900 shares of the company’s stock after acquiring an additional 3,300 shares during the period. Vestcor Inc’s holdings in BioNTech were worth $1,128,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Fred Alger Management LLC bought a new stake in shares of BioNTech during the third quarter worth $59,485,000. Charles Schwab Investment Management Inc. boosted its stake in shares of BioNTech by 123.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 134,036 shares of the company’s stock valued at $15,919,000 after purchasing an additional 74,119 shares during the last quarter. SG Americas Securities LLC raised its stake in shares of BioNTech by 412.3% during the fourth quarter. SG Americas Securities LLC now owns 41,470 shares of the company’s stock worth $4,726,000 after buying an additional 33,375 shares during the last quarter. Mirabaud & Cie SA acquired a new position in BioNTech in the fourth quarter valued at approximately $684,000. Finally, Redmile Group LLC bought a new position in BioNTech in the third quarter valued at approximately $18,345,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on the stock. JPMorgan Chase & Co. dropped their target price on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating for the company in a research report on Tuesday, November 26th. Morgan Stanley dropped their price objective on BioNTech from $145.00 to $139.00 and set an “overweight” rating for the company in a report on Tuesday, March 11th. Evercore ISI upgraded BioNTech from an “in-line” rating to an “outperform” rating and raised their target price for the stock from $110.00 to $125.00 in a report on Tuesday, November 19th. Citigroup started coverage on shares of BioNTech in a research report on Thursday. They issued a “buy” rating and a $145.00 price target on the stock. Finally, Canaccord Genuity Group restated a “buy” rating and set a $171.44 price objective on shares of BioNTech in a report on Tuesday, March 11th. Three analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, BioNTech currently has a consensus rating of “Moderate Buy” and a consensus target price of $143.73.

BioNTech Stock Performance

Shares of BNTX opened at $99.47 on Friday. The stock has a market capitalization of $23.85 billion, a price-to-earnings ratio of -47.37 and a beta of 0.30. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49. The firm has a fifty day simple moving average of $115.49 and a 200 day simple moving average of $113.19. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.24 billion. During the same quarter last year, the company earned $1.90 EPS. BioNTech’s revenue for the quarter was down 19.5% compared to the same quarter last year. Research analysts forecast that BioNTech SE will post -3.88 EPS for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.